stockrowChampions Oncology, Inc.
CSBR Healthcare Biotechnology
Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025.
- Revenue
- +8.84%
- EPS
- 0.00%
- Free cash flow
- −198.7%
Quarter to July 2026, against a year earlier
Follow CSBR
Alert me
Champions Oncology, Inc. (CSBR) EV/Sales
As of 6 November 2026, Champions Oncology, Inc. (CSBR) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from 0.7× (December 2022) to 8.9× (September 2018); the current reading is higher than 5% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 1.3× | (15.41%) |
| FY2025 | 1.5× | 22.64% |
| FY2024 | 1.3× | 21.64% |
| FY2023 | 1.0× | (44.58%) |
| FY2022 | 1.9× | (43.76%) |
| FY2021 | 3.3× | 28.34% |
| FY2020 | 2.6× | (29.79%) |
| FY2019 | 3.7× | 59.30% |
| FY2018 | 2.3× | 43.85% |
| FY2017 | 1.6× | (44.84%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jul 2026 | 1.2× | (11.42%) |
| Apr 2026 | 1.3× | (17.67%) |
| Jan 2026 | 1.6× | 7.94% |
| Oct 2025 | 1.5× | 8.76% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CNXU Conexeu Sciences Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| CSBR Champions Oncology, Inc. | 1.0× |
| COYA Coya Therapeutics, Inc. compare | 4.9× |
| NTRB Nutriband Inc. compare | 39.8× |
| MNOV MediciNova, Inc. compare | 50.5× |
| NORD Nordicus Partners Corporation compare | 79.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)